Literature DB >> 26698111

Altered Cell Cycle Arrest by Multifunctional Drug-Loaded Enzymatically-Triggered Nanoparticles.

Can Huang1, Ying Sun1, Ming Shen1, Xiangyu Zhang1, Pei Gao1, Yourong Duan1.   

Abstract

cRGD-targeting matrix metalloproteinase (MMP)-sensitive nanoparticles [PLGA-PEG1K-cRGD/PLGA-peptide-PEG5K (NPs-cRGD)] were successfully developed. Au-Pt(IV) nanoparticles, PTX, and ADR were encapsulated into NPs-RGD separately. The effects of the drug-loaded nanoparticles on the cell cycle were investigated. Here, we showed that higher cytotoxicity of drug-loaded nanoparticles was related to the cell cycle arrest, compared to that of free drugs. The NPs-cRGD studied here did not disrupt cell cycle progression. The cell cycle of Au-Pt(IV)@NPs-cRGD showed a main S phase arrest in all phases of the cell cycle phase, especially in G0/G1 phase. PTX@NPs-cRGD and ADR@NPs-cRGD showed a higher ratio of G2/M and S phase arrest than the free drugs, respectively. Cells in G0/G1 and S phases of the cell cycle had a higher uptake ratio of NPs-cRGD. A nutrient deprivation or an increase in the requirement of nutrients in tumor cells could promote the uptake of nanoparticles from the microenvironments. In vivo, NPs-cRGD could efficiently accumulate at tumor sites. The inhibition of tumor growth coupled with cell cycle arrest is in line with that in vitro. On the basis of our results, we propose that future studies on nanoparticle action mechanism should consider the cell cycle, which could be different from free drugs. Understanding the actions of cell cycle arrest could affect the application of nanomedicine in the clinic.

Entities:  

Keywords:  cell cycle; chemotherapy; matrix metalloproteinase; nanoparticles; targeting

Mesh:

Substances:

Year:  2016        PMID: 26698111     DOI: 10.1021/acsami.5b10241

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  6 in total

1.  Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.

Authors:  Zhaojun Li; Hui Huang; Lili Huang; Lianfang Du; Ying Sun; Yourong Duan
Journal:  Int J Mol Sci       Date:  2017-04-13       Impact factor: 5.923

2.  GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer.

Authors:  Hui Huang; Yang Dong; Yanhua Zhang; Dan Ru; Zhihua Wu; Jiali Zhang; Ming Shen; Yourong Duan; Ying Sun
Journal:  Theranostics       Date:  2019-01-30       Impact factor: 11.556

3.  Cetuximab-conjugated perfluorohexane/gold nanoparticles for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment.

Authors:  Ying Liu; Yue Ma; Xiaoshan Peng; Lingling Wang; Haixia Li; Wen Cheng; Xiulan Zheng
Journal:  Sci Technol Adv Mater       Date:  2021-02-01       Impact factor: 8.090

4.  Poly(l-glutamic acid)-cisplatin nanoformulations with detachable PEGylation for prolonged circulation half-life and enhanced cell internalization.

Authors:  Zhongyu Jiang; Xiangru Feng; Haoyang Zou; Weiguo Xu; Xiuli Zhuang
Journal:  Bioact Mater       Date:  2021-02-13

5.  Evaluation of apoptotic effects of mPEG-b-PLGA coated iron oxide nanoparticles as a eupatorin carrier on DU-145 and LNCaP human prostate cancer cell lines.

Authors:  Marziyeh Shalchi Tousi; Houri Sepehri; Sepideh Khoee; Mahdi Moridi Farimani; Ladan Delphi; Fariba Mansourizadeh
Journal:  J Pharm Anal       Date:  2020-04-18

6.  Dual-mode US/MRI nanoparticles delivering siRNA and Pt(iv) for ovarian cancer treatment.

Authors:  Yanhua Zhang; Hui Huang; Hao Fu; Meng Zhao; Zhihua Wu; Yang Dong; He Li; Yourong Duan; Ying Sun
Journal:  RSC Adv       Date:  2019-10-17       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.